NTRK1 and neoplasm: Tyrosine kinase receptor-blocking antibodies, like cetuximab for EGFR, have a dual mechanism of action: the variable regions block receptor–ligand interactions to induce intrinsic effects on tumor cells, and the Fc binds Fcγ receptors in leukocytes that induce cellular immunity.